Richard Pazdur
0000-0002-4771-9923
Publication & Citation Trends
Publications
0 total
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. OA
Cited by 10
Semantic Scholar
Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests.
Cited by 1
Semantic Scholar
FDA Approval Summary: Eflornithine for High-Risk Neuroblastoma Following Prior Multiagent, Multimodality Therapy.
Cited by 6
Semantic Scholar
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit
Cited by 3
Semantic Scholar
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations
Cited by 25
Semantic Scholar
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. OA
Cited by 14
Semantic Scholar
Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship. OA
Cited by 0
Semantic Scholar
RE: is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?
Cited by 0
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(144)
Cancer Immunotherapy and Biomarkers
(133)
Cancer Treatment and Pharmacology
(123)
Lung Cancer Treatments and Mutations
(119)
Health Systems, Economic Evaluations, Quality of Life
(107)
Affiliations
University of Maryland, Baltimore
Rush University Medical Center
National Institutes of Health
Main Line Health
Center for Biologics Evaluation and Research